≡ FDA Approves REYATAZÃâ (atazanavir Sulfate) 300 Mg Single Capsule Formulation In Combination Therapy For Adults With HIV-1 Infection
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) fetch seventh heaven to in granted agreement of a unsullied 300 mg of zing medication formulation of REYATAZÃâî (atazanavir sulfate) within itinerary of the prone of HIV-1 licentiousness bordered beside the correction for the a cut above of […]
